Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DARE |
---|---|---|
09:32 ET | 48794 | 0.54 |
09:34 ET | 11900 | 0.5402 |
09:36 ET | 200 | 0.55 |
09:38 ET | 5847 | 0.54 |
09:39 ET | 1060 | 0.5102 |
09:41 ET | 100 | 0.511928 |
09:45 ET | 1392 | 0.5251 |
09:48 ET | 500 | 0.5326 |
09:50 ET | 550 | 0.54 |
09:52 ET | 5128 | 0.51 |
09:54 ET | 721 | 0.54 |
09:57 ET | 7400 | 0.55 |
09:59 ET | 3966 | 0.5101 |
10:03 ET | 1200 | 0.5399 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Dare Bioscience Inc | 54.1M | -1.1x | --- |
Curis Inc | 64.1M | -1.2x | --- |
Ikena Oncology Inc | 67.1M | -0.9x | --- |
Bolt Biotherapeutics Inc | 46.5M | -0.7x | --- |
DURECT Corp | 40.0M | -1.1x | --- |
Spruce Biosciences Inc | 30.5M | -0.6x | --- |
Dare Bioscience, Inc. is a biopharmaceutical company. The Company is engaged in identifying, developing, and marketing a portfolio of differentiated therapies that prioritize women's health and well-being, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Its first product, XACIATO, is a clindamycin phosphate vaginal gel used for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1 and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-GML, DARE-LBT, and DARE-RH1. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream 3.6% is a proprietary cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder (FSAD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.1M |
---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 98.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.17 |
EPS | $-0.48 |
Book Value | $0.13 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 54.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,199.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.